1. Background {#sec1-jcm-09-00689}
=============

Pancreatic cancer is an aggressive disease with poor prognosis. Due to its tendency to remain asymptomatic until it reaches an advanced stage, it is difficult to diagnose and typically deemed unresectable at the time of diagnosis. When deemed operable, pancreatectomy is considered as the best option in terms of longer survival \[[@B1-jcm-09-00689]\]. Pancreatectomy in this article refers to all types of curative-intent surgery for pancreatic cancer which includes pancreatoduodenectomy, pylorus preserving pancreatoduodenectomy, total pancreatectomy and distal pancreatectomy. However, even when some pancreatic cancers are discovered at a potentially operable stage, pancreatectomy survival rate is very poor compared to other types of resected cancers \[[@B2-jcm-09-00689]\].

Factors concerning poor prognosis of pancreatic cancers include high level of CA19-9, large tumor size, lymph node metastasis, and perineural and lymphovascular invasion \[[@B3-jcm-09-00689],[@B4-jcm-09-00689],[@B5-jcm-09-00689],[@B6-jcm-09-00689]\]. However, these factors cannot be controlled by surgeons and occur before pancreatectomy is performed. Thus, instead of examining such uncontrollable prognostic factors, we aim to identify the factors that can be controlled either at the time of or after surgery. Although adjuvant chemotherapy and radiotherapy can be performed after surgery, we decided to manipulate the timeline of surgery. Factors such as availability of combined resection, operation time, amount of blood loss, and availability of transfusion are decided at the time of surgery and could play a role in improving survival and recurrence rates of patients who undergo pancreatectomy. Of these factors, we focused on transfusion and their inappropriate performance during pancreatectomy and hypothesized that reduction of such inappropriate transfusions could improve patient outcomes \[[@B7-jcm-09-00689]\]. Given that the interactions of the host immune system and cancer microenvironment play an important role in determining outcome, and the fact that transfusion lowers a patient's immunity and aggravates outcome \[[@B8-jcm-09-00689],[@B9-jcm-09-00689]\], we concluded that intraoperative transfusion (IOT) might lead to poor outcome.

There have been many studies underlining the poor effects of transfusion performed during pancreatic cancer surgery on patient outcomes. Most, however, focus on the effect of IOT on recurrence and survival in pancreaticoduodenectomy cases and not in other types of pancreatectomy, because of the complicated procedure of pancreaticoduodenectomy \[[@B10-jcm-09-00689],[@B11-jcm-09-00689],[@B12-jcm-09-00689]\]. One particular study suggests that transfusion performed during pancreatectomy for left-sided pancreatic cancer patients is harmful \[[@B7-jcm-09-00689]\]. While that study focused on more than just pancreaticoduodenectomy, it involved a small number of subjects and focused only on left-sided pancreatic cancer; therefore, it is unlikely to provide a strong guideline against transfusion during pancreatic cancer surgery. Thus, we performed our study on a larger number of subjects and widened the scope to involve all types of pancreatectomy. By doing so, we hope to provide strong evidence that IOT has a negative effect on the prognosis of patients undergoing pancreatectomy. The purpose of this study is to investigate the oncologic impact of IOT in all types of pancreatectomy.

2. Materials and Methods {#sec2-jcm-09-00689}
========================

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Severance Hospital (registered on 3 March 2019, and registration number is 2019-0526-001). All patients who underwent pancreatectomy in Severance Hospital of Yonsei University College of Medicine from June 2004 to January 2014 were enrolled in this study to evaluate the oncologic impact of IOT in all types of pancreatectomy. Patients diagnosed with metastatic disease (*n* = 3) and locally advanced diseases (*n* = 15) were excluded during the analysis, and total of 287 patients were analyzed. All patients' medical records were retrospectively reviewed. We analyzed clinicopathological features, intra-operative findings (including combined resection of other organs or vascular structures), operation types, neo-adjuvant chemoradiation therapy, TNM (tumor, nodes and metastases) stage by 8th AJCC classification, postoperative complications, and survival outcomes. The patients with a pathologic diagnosis of only ductal adenocarcinoma were enrolled, and those with other pathologic conditions of the pancreas were excluded to create a homogenous patient population. IOT was defined as any amount of red blood cell transfusion received during the operative procedure. Details pertaining to the amount of bleeding during operation were evaluated based on operative medical records. Continuous variables are expressed as mean ± SD (standard deviation), and nominal variables are expressed as frequency (%). Comparative analysis was performed using the Chi-square test and Student's *t*-test. Survival analysis was calculated using the Kaplan-Meier method, and the significance of a difference between groups was assessed with a log rank test. Multivariate analysis was performed to identify risk factors of cancer recurrence and survival rate using a Cox proportional hazards model. P-values less than 0.05 were considered statistically significant.

3. Results {#sec3-jcm-09-00689}
==========

3.1. General Characteristics of the Patients {#sec3dot1-jcm-09-00689}
--------------------------------------------

During the study period, 287 patients underwent pancreatectomy for pancreatic ductal adenocarcinoma ([Table 1](#jcm-09-00689-t001){ref-type="table"}). The 113 female patients (39.4%) and 174 male patients (60.6%) had an average age of 62.5 ± 9.5 years. Fifty-seven patients (19.9%) were asymptomatic. Eighty-one patients (28.2%) underwent neo-adjuvant chemotherapy prior to surgery, while another 206 patients (71.8%) underwent upfront surgery. Seventeen patients underwent PD (pancreatoduodenectomy) (5.9%), 162 patients underwent PPPD (Pylorus preserving pancreatoduodenectomy) (56.4%), 101 patients underwent DP (distal pancreatectomy) (35.2%), and 7 patients underwent TP (Total pancreatectomy) (2.4%). Combined resection was performed in 93 patients (32.4%). Two hundred and forty-nine patients (86.8%) underwent R0 resection. Post-operative adjuvant chemotherapy was provided in 211 patients (73.5%). Post-operative mortality occurred in 3 patients (1.0%), and patients with other complications were assorted according to Clavien-Dindo Classification. It was noted that 69 patients (24.0%) had IOT ([Table 1](#jcm-09-00689-t001){ref-type="table"}).

3.2. Chronological Trend and Potential Adverse Oncologic Impact of IOT {#sec3dot2-jcm-09-00689}
----------------------------------------------------------------------

The incidence of IOT declined significantly during the time period (*P* = 0.004, Chi-square with linear-to-linear association, [Figure 1](#jcm-09-00689-f001){ref-type="fig"}). In the early period (2004\~2007), 28.6% of the patients (16 out of 56 patients) who underwent radical pancreatectomy for pancreatic cancer received IOT; during the last period (2012--2014), IOT was performed in only 13.9% of the patients (16 out of 115 patients).

The disease-specific survival rate of the patients who received IOT showed was significantly poorer compared to that of the group of patients that did not undergo transfusion during surgery (median survival of 20 months (95% CI: 18--22) vs. median survival of 33 months (95% CI: 27--38), *P* = 0.010, [Figure 2](#jcm-09-00689-f002){ref-type="fig"}a). The recurrence rate also showed a significant difference between the two groups, with *P* = 0.031. The median recurrence interval of patients who underwent IOT was 11 months (95% CI: 8--13), and that of patients who did not undergo IOT was 12 months (95% CI: 10--15, [Figure 2](#jcm-09-00689-f002){ref-type="fig"}b).

3.3. Determining Prognostic Factors in Resected Pancreatic Cancer {#sec3dot3-jcm-09-00689}
-----------------------------------------------------------------

In univariate analysis ([Table 2](#jcm-09-00689-t002){ref-type="table"}), IOT (HR = 1.41 \[95% CI: 1.03--1.94\], *P* = 0.031) was associated with tumor recurrence. Also, IOT (HR = 1.55 \[95% CI: 1.10--2.17\], *P* = 0.011), T status (T3&T4, HR = 1.75 \[95% CI: 1.04--2.95\], *P* = 0.033), N status (N1&N2, HR = 1.65 \[95% CI: 1.20--2.26\], *P* = 0.002) were associated with disease-specific survival rate in resected pancreatic cancer.

Multivariate analysis was performed on factors with p-value less than 0.1 in univariate analysis and was adjusted with the following cofounding factors; IOT, gender, NeoCRT, Adj. CTx, combined resection, complications, T status, N status, R status, past history, operation time, age, symptoms, preoperative CA19-9 level, EBL, tumor location, resectability, combined resection, complications, surgery type, LVI, PNI, and the year surgery was performed. The analysis showed that T status (HR = 2.04, \[95% CI: 1.13--3.68\], *P* = 0.018), N status (HR = 1.46 \[95% CI: 1.00--2.12\], *P* = 0.045), Adj.CTx (HR = 0.51, \[95% CI: 0.35--0.75\], *P* = 0.001), IOT (HR = 1.94 \[95% CI: 1.23--3.07\], *P* = 0.004), were independent prognostic factors of disease-specific survival after surgery ([Table 3](#jcm-09-00689-t003){ref-type="table"}). As well, Adj.CTx (HR = 0.67, \[95% CI: 0.46--0.97\], *P* = 0.035) was independently associated with tumor recurrence ([Table 3](#jcm-09-00689-t003){ref-type="table"}).

3.4. Predicting IOT in Resected Pancreatic Cancer {#sec3dot4-jcm-09-00689}
-------------------------------------------------

It was analyzed that combined organ resection (*P* \< 0.001), and EBL (*P* \< 0.001) and the year surgery was performed (*P* = 0.004) were significantly related to IOT. Therefore, IOT group correlated with higher amount of EBL. However, there were no significant differences between age, gender, past history, symptoms, complications between the group that went through IOT and the group that did not. (*P* \> 0.05) Additionally, differences between the two groups regarding T status, N status, M stage, neoadjuvant chemoradiation therapy, adjuvant chemotherapy, tumor location, lymphovascular invasion, perineural invasion, resectability of tumors, surgery types, operation time, curative resection between the two groups were also analyzed: there was no differences the two groups. (*P* \> 0.05).

4. Discussion {#sec4-jcm-09-00689}
=============

There have been several studies \[[@B13-jcm-09-00689],[@B14-jcm-09-00689],[@B15-jcm-09-00689]\] concerning methods to improve surgical outcomes of resected pancreatic cancer during the past years, though none have achieved great success. The 5-year survival rate of overall pancreatic cancer is still 9%, and even for the small portion of people who are diagnosed with localized tumor and deemed operable, the 5-year survival is only 37% which is very poor compared with other types of tumors \[[@B2-jcm-09-00689],[@B16-jcm-09-00689]\].

Although factors that have an influence on resected pancreatic patient survival and tumor recurrence rates have been defined by many researchers \[[@B3-jcm-09-00689],[@B4-jcm-09-00689],[@B5-jcm-09-00689],[@B6-jcm-09-00689],[@B17-jcm-09-00689]\], there are few studies concerning factors changeable by surgeons during the intraoperative timeline. Our study showed that T status, N status, and Adj.CTx were independent prognostic factors associated with tumor recurrence and disease specific survival rates in resected pancreatic cancer ([Table 3](#jcm-09-00689-t003){ref-type="table"}). However, the importance of this study is that IOT can be considered as an independent prognostic factor associated with survival outcomes of resected pancreatic cancer (*P* = 0.004, [Table 3](#jcm-09-00689-t003){ref-type="table"}).

Many studies have revealed the negative effect of blood transfusion on patient survival in various kinds of resected cancers by showing patients receiving perioperative blood transfusions have a significantly worse prognosis than patients undergoing cancer surgery without a perioperative transfusion \[[@B18-jcm-09-00689],[@B19-jcm-09-00689],[@B20-jcm-09-00689],[@B21-jcm-09-00689],[@B22-jcm-09-00689]\]. However, few studies have analyzed the impact of IOT on oncologic outcomes of pancreatectomy. A previous study reported by Hwang et al. \[[@B7-jcm-09-00689]\] suggested that IOT in left-sided pancreatic cancer is a prognostic factor associated with tumor recurrence among patients who underwent pancreatectomy. However, their study focused only on left-sided pancreatic cancer and involved a relatively small number of subjects. Therefore, it remained controversial whether transfusion has a detrimental effect on resected pancreatic cancer.

Although it is hard to argue the idea that IOT is only the aftermath of the large blood loss which represents tumor's size and surgery type, combined resection, and patient's overall health and not the prognostic factor itself, by using multivariate analysis which was adjusted with many confounding factors, we were able to prove IOT is an independent prognostic factor of resected pancreatic cancer. As well, among the factors defined to have an impact on disease-specific survival of resected pancreatic cancer, IOT was the only factor that can be controlled by surgeons during the intraoperative period. Since EBL was significantly associated with transfusion during surgery (*P* \< 0.001, [Table 4](#jcm-09-00689-t004){ref-type="table"}), we concluded that surgeons should take precautions to reduce bleeding during pancreatectomy and thereby reduce the chance of IOT. To improve the oncologic outcomes of patients who undergo pancreatectomy, bleeding should be avoided by applying advanced surgical techniques based on anatomical knowledge, and inappropriate transfusion should be avoided by following a strict transfusion policy in consensus with the anesthesiology department. Also, although invasive pancreatectomy for pancreatic cancer is still controversial, based on the present observation that EBL was found to be the one of the significant factors contributing to IOT, minimally invasive pancreatectomy may have potential rationale in managing resectable pancreatic cancer. Many literature reviews and meta-analysis suggested that laparoscopic and robotic pancreatectomy were strongly associated with less EBL and less incidence of IOT \[[@B23-jcm-09-00689],[@B24-jcm-09-00689],[@B25-jcm-09-00689],[@B26-jcm-09-00689],[@B27-jcm-09-00689],[@B28-jcm-09-00689],[@B29-jcm-09-00689],[@B30-jcm-09-00689]\].

However, our present study has several limitations. Firstly, our study was a single-center, retrospective study with a limited number of patients. If the study was conducted with more subjects in multi-center, the results would have been more powerful. Hence, further research is needed. By using broad clinical data from Korean multicenter research and Korea-Japan joint research, more powerful evidence for prognosis of transfusion in resected pancreatic cancer could be made. Also, through prospective cohort study of strict transfusion policy, a comparative study using propensity score matching can be envisioned. Secondly, our study failed to support an association between tumor recurrence and IOT. Although a Kaplan-Meier curve (*P* = 0.031, [Figure 2](#jcm-09-00689-f002){ref-type="fig"}b) and univariate analysis showed that IOT was strongly associated with tumor recurrence (*P* = 0.031, [Table 2](#jcm-09-00689-t002){ref-type="table"}), subsequent multivariate analysis indicated that IOT is not accurately associated with tumor recurrence in resected pancreatic cancer (*P* = 0.056, [Table 3](#jcm-09-00689-t003){ref-type="table"}). Again, with study conducted with more subjects in multi-center, the result may indicate IOT as a prognostic factor for tumor recurrence.

In summary, IOT was strongly associated with poorer survival outcomes of resected pancreatic cancer. Although the trend of performing IOT on resected pancreatic cancer is declining, more strict actions should be applied to achieve better outcomes. IOT is thought to be a controllable factor that can be managed, and it can be achieved not only by improving surgical technique such as minimal invasive surgery, but also by implementing an intraoperative transfusion guideline in cooperation with the anesthesiologic department.

S.Y.K. had the idea for this research, designed the study and was a major contributor in writing the manuscript. M.C. revised the manuscript. H.K.H., S.Y.R., W.J.L., have made substatial contributions in acquistion and interpretation of data. C.M.K. conceived and designed the study, revised, and gave final approval to the manuscript. All authors have read and agreed to the published version of the manuscript.

This research received no external funding.

The authors declare that they have no competing interests.

![Trend of IOT (intraoperative transfusion) according to time period.](jcm-09-00689-g001){#jcm-09-00689-f001}

![Long-term oncologic outcomes of resected pancreatic cancer according to IOT (**a**) represents the comparison of disease-specific survival rates between the patients who received IOT and those who did not. (**b**) represents the comparison of recurrence rates between the patients who received IOT and those who did not.](jcm-09-00689-g002){#jcm-09-00689-f002}

jcm-09-00689-t001_Table 1

###### 

General characteristics of the patients.

  Variables                                      Value
  ---------------------------------------------- ---------------
  Age (years)                                    62.5 ± 9.5
  Sex                                            
  Female                                         113 (39.4)
  Male                                           174 (60.6)
  Past history                                   
  No                                             75 (26.1)
  Yes                                            212 (73.9)
  Symptoms                                       
  No                                             57 (19.9)
  Yes                                            230 (80.1)
  Complications (Clavien-Dindo Classification)   
  None                                           135 (47.0)
  Grade 1                                        98 (34.1)
  Grade 2                                        17 (5.9)
  Grade 3                                        24 (8.4)
  Grade 4                                        10 (3.5)
  Grade 5                                        3 (1.0)
  T status                                       
  T0, T1, T2                                     262 (91.3)
  T3, T4                                         25 (8.7)
  N status                                       
  N0                                             137 (47.7)
  N1, N2                                         150 (52.3)
  Preoperative CA19_9                            719.6 ± 202.7
  Neo CRT (Neoadjuvant chemoradiation therapy)   
  No                                             206 (71.8)
  Yes                                            81 (28.2)
  Adj. CTx (Adjuvant chemotherapy)               
  No                                             76 (26.5)
  Yes                                            211 (73.5)
  Tumor location                                 
  Head                                           111 (38.7)
  Uncinate                                       66 (23.0)
  Neck                                           6 (2.1)
  Body                                           63 (22.0)
  Tail                                           35 (12.2)
  Body + tail                                    6 (2.1)
  LVI (Lymphovascular invasion)                  
  No                                             198 (69.0)
  Yes                                            89 (31.0)
  PNI (Perineural invasion)                      
  No                                             106 (36.9)
  Yes                                            181 (63.1)
  Resectability                                  
  Resectable                                     215 (74.9)
  Borderline                                     72 (25.1)
  Surgery type                                   
  PD                                             17 (5.9)
  PPPD                                           162 (56.4)
  DP                                             101 (35.2)
  TP                                             7 (2.4)
  Operation time (min)                           392.6 ± 148.5
  Combined resection                             
  No                                             194 (67.6)
  Yes                                            93 (32.4)
  Curative resection                             
  R0                                             249 (86.8)
  R1                                             34 (11.8)
  R2                                             4 (1.4)
  EBL (mL)                                       654.8 ± 215.5
  IOT                                            
  No                                             218 (76.0)
  Yes                                            69 (24.0)

Notes: All data are expressed as mean ± SD or N (%) Abbreviations: PD, pancreatoduodenectomy; PPPD. Pylorus preserving pancreatoduodenectomy; DP, distal pancreatectomy; TP, Total pancreatectomy; Neo CRT, Neoadjuvant chemoradiation therapy; Adj. CTx, Adjuvant chemotherapy; LVI, Lymphovascular invasion; PNI, Perineural invasion; IOT, intraoperative transfusion; and EBL, Estimated blood loss.

jcm-09-00689-t002_Table 2

###### 

Prognostic factors in resected pancreatic cancer: Univariate analysis.

  -----------------------------------------------------------------------------------------------
  Variables             Disease-Specific Survival\   Recurrence\                          
                        (Event = 162)                (Event = 191)                        
  --------------------- ---------------------------- --------------- -------------------- -------
  Age                                                0.476                                0.505

  \<63                  Ref                                          Ref                  

  ≥63                   1.12 (0.81--1.53)                            0.90 (0.68--1.20)    

  Sex                                                0.156                                0.683

  Male                  Ref                                          Ref                  

  Female                1.36 (0.99--1.88)                            1.06 (0.79--1.41)    

  Past history                                       0.716                                0.741

  No                    Ref                                          Ref                  

  Yes                   1.06 (0.75--1.49)                            0.94 (0.69--1.30)    

  Symptoms                                           0.127                                0.118

  No                    Ref                                          Ref                  

  Yes                   1.27 (0.93--1.74)                            1.24 (0.94--1.67)    

  Complications                                      0.28                                 0.734

  None                  Ref                                          Ref                  

  Grade 1               0.88 (0.63--1.25)                            0.94 (0.68--1.29)    

  Grade 2               0.65 (0.30--1.41)                            0.64 (0.32--1.27)    

  Grade 3               0.45 (0.22--0.89)                            0.64 (0.37--1.12)    

  Grade 4               0.66 (0.27--1.64)                            1.32 (0.64--2.73)    

  Grade 5               1.04 (0.25--4.29)                            0.49 (0.06--3.53)    

  T status                                           0.033                                0.482

  T0/T1/T2              Ref                                          Ref                  

  T3/T4                 1.75 (1.04--2.95)                            1.20 (0.71--2.00)    

  N status                                           0.002                                0.668

  N0                    Ref                                          Ref                  

  N1/N2                 1.65 (1.20--2.26)                            1.05 (0.79--1.40)    

  Preoperative CA19_9                                0.796                                0.553

  \<750                 Ref                                          Ref                  

  ≥750                  1.05 (0.72--1.53)                            1.10 (0.78--1.56)    

  NeoCRT                                             0.711                                0.612

  No                    Ref                                          Ref                  

  Yes                   0.96 (0.68--1.36)                            1.08 (0.79--1.48)    

  Adj CTx                                            0.061                                0.082

  No                    Ref                                          Ref                  

  Yes                   0.68 (0.49--0.96)                            0.86 (0.62--1.19)    

  Tumor location                                     0.375                                0.824

  Head                  Ref                                          Ref                  

  Uncinate              1.09 (0.71--1.68)                            1.04 (0.71--1.51)    

  Neck                  2.66 (1.06--6.68)                            2.80 (1.12--7.01)    

  Body                  0.88 (0.58--1.34)                            0.71 (0.47--1.05)    

  Tail                  1.61 (1.01--2.57)                            1.53 (0.99--2.37)    

  Body + Tail           0.59 (0.18--1.88)                            0.45 (0.14--1.44)    

  LVI                                                0.084                                0.292

  No                    Ref                                          Ref                  

  Yes                   1.33 (0.96--1.84)                            1.17 (0.86--1.59)    

  PNI                                                0.597                                0.393

  No                    Ref                                          Ref                  

  Yes                   1.08 (0.79--1.49)                            1.13 (0.84--1.52)    

  Resectability                                      0.459                                0.23

  Resectable            Ref                                          Ref                  

  Borderline            0.86 (0.59--1.25)                            1.21 (0.88--1.67)    

  Surgery type                                       0.08                                 0.202

  PD                    Ref                                          Ref                  

  PPPD                  0.58 (0.31--1.06)                            1.55 (0.78--3.06)    

  DP                    0.56 (0.30--1.04)                            1.23 (0.61--2.50)    

  TP                    1.23 (0.34--4.39)                            4.66 (1.72--12.58)   

  Operation time                                     0.778                                0.845

  \<400                 Ref                                          Ref                  

  ≥400                  1.05 (0.73--1.51)                            1.03 (0.73--1.45)    

  Combined resection                                 0.285                                0.07

  No                    Ref                                          Ref                  

  Yes                   1.19 (0.86--1.66)                            1.31 (0.97--1.77)    

  Curative resection                                 0.703                                0.765

  R0                    Ref                                          Ref                  

  R1/R2                 1.09 (0.68--1.75)                            0.93 (0.59--1.45)    

  EBL                                                0.778                                0.646

  \<650                 Ref                                          Ref                  

  ≥650                  1.03 (0.73--1.51)                            1.06 (0.80--1.42)    

  IOT                                                0.011                                0.031

  No                    Ref                                          Ref                  

  Yes                   1.55 (1.10--2.17)                            1.41 (1.03--1.94)    

  Period                                             0.631                                0.772

  2004--2007            Ref                                          Ref                  

  2008--2011            1.04 (0.71--1.52)                            1.05 (0.72--1.54)    

  2012--2014            0.89 (0.57--1.40)                            1.67 (0.72--1.59)    
  -----------------------------------------------------------------------------------------------

Abbreviations: PD, pancreatoduodenectomy; PPPD. Pylorus preserving pancreatoduodenectomy; DP, distal pancreatectomy; TP, Total pancreatectomy; Neo CRT, Neoadjuvant chemoradiation therapy; Adj. CTx, Adjuvant chemotherapy; LVI, Lymphovascular invasion; PNI, Perineural invasion; IOT, intraoperative transfusion; and EBL, Estimated blood loss.

jcm-09-00689-t003_Table 3

###### 

Prognostic factors in resected pancreatic cancer: Multivariate analysis.

  -------------------------------------------------------------------------------------------------
  Variables            Disease-Specific Survival\   Recurrence\                             
                       (Event = 162)                (Event = 191)                           
  -------------------- ---------------------------- ------------------- ------------------- -------
  T status                                          0.018                                   

  T0/T1/T2             Ref                                                                  

  T3/T4                2.04 (1.13--3.68)                                                    

  N status                                          0.045                                   

  N0                   Ref                                                                  

  N1, N2               1.46 (1.00--2.12)                                                    

  LVI                                               0.225                                   

  No                   Ref                                                                  

  Yes                  1.25 (0.86--1.82)                                                    

  Surgery type                                      0.126                                   

  PD                   Ref                                                                  

  PPPD                 0.43 (0.20--0.89)                                                    

  DP                   0.41 (0.13--1.28)                                                    

  TP                   0.97 (0.22--4.25)                                                    

  Adj.CTx                                           0.001                                   0.035

  No                   Ref                                              Ref                 

  Yes                  0.51 (0.35--0.75)                                0.67 (0.46--0.97)   

  IOT                                               0.004                                   0.056

  No                   Ref                                              Ref                 

  Yes                  1.94 (1.23--3.07)                                1.47 (0.99--2.20)   

  Combined resection                                                                        0.727

  No                                                Ref                                     

  Yes                                               0.93 (0.64--1.35)                       
  -------------------------------------------------------------------------------------------------

Abbreviations: Adj. CTx, Adjuvant chemotherapy; LVI, Lymphovascular invasion; and IOT, intraoperative transfusion.

jcm-09-00689-t004_Table 4

###### 

Predicting IOT in resected pancreatic cancer.

  Variables             IOT          *P*-Value   
  --------------------- ------------ ----------- ----------
  Age                                            0.356
  \<63                  96 (44.0)    26 (37.7)   
  ≥63                   122 (56.0)   43 (62.3)   
  Sex                                            0.747
  Male                  87 (39.9)    26 (37.7)   
  Female                131 (60.1)   43 (62.3)   
  Past history                                   0.751
  No                    58 (26.6)    17 (24.6)   
  Yes                   160 (73.4)   52 (75.4)   
  Symptoms                                       0.189
  No                    53 (24.3)    4 (5.7)     
  Yes                   165 (75.6)   65 (94.3)   
  Complications                                  0.293
  None                  101 (46.3)   34 (49.3)   
  Grade 1               76 (34.9)    22 (31.9)   
  Grade 2               11 (5.0)     6 (8.7)     
  Grade 3               22 (10.1)    2 (2.9)     
  Grade 4               6 (2.8)      4 (5.8)     
  Grade 5               2 (0.9)      1 (1.4)     
  T status                                       0.638
  T0/T1/T2              200 (91.7)   62 (89.9)   
  T3/T4                 18 (8.3)     7 (10.1)    
  N status                                       0.285
  N0                    108 (49.5)   29 (42.0)   
  N1/N2                 110 (50.5)   40 (58.0)   
  Preoperative CA19_9                            0.058
  \<750                 178 (81.7)   49 (71.0)   
  ≥750                  40 (18.3)    20 (29.0)   
  NeoCRT                                         0.167
  No                    168 (77.1)   38 (55.1)   
  Yes                   50 (22.9)    31 (44.9)   
  Adj CTx                                        0.932
  No                    58 (26.6)    18 (26.1)   
  Yes                   160 (73.4)   51 (73.9)   
  Tumor location                                 0.065
  Head                  74 (33.9)    37 (53.6)   
  Uncinate              50 (22.9)    20 (23.2)   
  Neck                  6 (2.8)      0 (0.0)     
  Body                  50 (22.9)    13 (18.8)   
  Tail                  32 (14.7)    3 (4.3)     
  Body + Tail           6 (2.8)      0 (0.00)    
  LVI                                            0.276
  No                    146 (67.0)   52 (75.4)   
  Yes                   72 (33.0)    17 (24.6)   
  PNI                                            0.674
  No                    78 (35.8)    28 (40.6)   
  Yes                   140 (64.2)   41 (59.4)   
  Resectability                                  0.651
  Resectable            175 (80.3)   40 (58.0)   
  Borderline            43 (19.7)    29 (42.0)   
  Surgery type                                   
  PD                    13 (6.0)     4 (5.8)     
  PPPD                  114 (52.3)   48 (69.6)   
  DP                    87 (39.9)    14 (20.3)   
  TP                    4 (1.8)      3 (4.3)     
  Operation time                                 0.064
  \<400                 123 (56.4)   14 (20.3)   
  ≥400                  95 (43.6)    55 (79.7)   
  Combined resection                             \<.0.001
  No                    167 (76.6)   27 (39.1)   
  Yes                   51 (23.4)    42 (60.9)   
  Curative resection                             0.641
  R0                    188 (86.2)   61 (88.4)   
  R1/R2                 30 (13.8)    8 (11.6)    
  EBL                                            \<0.001
  \<650                 145 (66.5)   10 (14.5)   
  ≥650                  73 (33.5)    59 (85.5)   
  Period                                         0.004
  2004--2007            40 (18.3)    16 (23.2)   
  2008--2011            79 (36.2)    37 (53.6)   
  2012--2014            99 (45.4)    16 (23.2)   

Abbreviations: PD, pancreatoduodenectomy; PPPD. Pylorus preserving pancreatoduodenectomy; DP, distal pancreatectomy; TP, Total pancreatectomy; Neo CRT, Neoadjuvant chemoradiation therapy; Adj. CTx, Adjuvant chemotherapy; LVI, Lymphovascular invasion; PNI, Perineural invasion; IOT, intraoperative transfusion; and EBL, Estimated blood loss.
